促紅細胞生成素與腫瘤相關性貧血研究進展_《華西醫學》

作者：

馮崗 , 王晉 , 張羽 , 周筱秋 , 任素蓉 , 杜小波 , 姚兵 , 李慧

四川省綿陽市中心醫院腫瘤科,四川綿陽 621000;

關鍵詞：

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

引用本文： 馮崗,王晉,張羽,周筱秋,任素蓉,杜小波,姚兵,李慧. 促紅細胞生成素與腫瘤相關性貧血研究進展. 華西醫學, 2009, 24(6): 1611-1613. doi: 復制

1.	LUDWIG H, BARRETT P, GASCON P, et al. European Cancer Anemia Survey (eECAS) defines factors surrounding anemia in thousands cancer patients[J]. Proc Am Soc Clin Oncol,2002,21:Abstract 1546.
2.	LADEROUTE K, ALARCON R, BRODY, et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor[J]. Clin Cancer Res,2000,(6):2941-2950.
3.	EBERT B L, BUNN H F. Regulation of the erythropoietin gene[J]. Blood,1999,94:1864-1877.
4.	WEISS M J. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications[J]. Oncologist,2003, 8 Suppl 3:18-29.
5.	JULIA B, SIMON L, GUIDO S, et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive Metaanalysis[J]. J Nat Cancer Inst,2005,97(7):489-498.
6.	http://www.fda.gov/cder/drug/advisory/RHE2007htm[OL].
7.	TSUBOI M, EZAKI K, TOBINAIi K, et al. Weekly administration of epoetin beta for chemotherapyinduced anemia in cancer patients: results of a multicenter, phase Ⅲ, randomized, doubleblind, placebocontrolled study[J]. Jpn J Clin Oncol,2009,39(3):163-168.
8.	AAPRO M, SCHERHAG A, BURGER H. Effect of treatment with epoetinbeta on survival, tumour progression and thromboembolic events in patients with cancer: an updated metaanalysis of 12 randomised controlled studies including 2301 patients[J]. Br J Cancer,2008,99(1):14-22.
9.	GLASPY J, CHARU V, LUO D, et al. Initiation of epoetinalpha therapy at a starting dose of 120000 units once every 3 weeks in patients with cancer receiving chemotherapy: an openlabel, multicenter study with randomized and nonrandomized treatment arms[J]. Cancer,2009,115(5):1121-1131.
10.	GLASER C, MILLESI W, KORNEK G, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx[J]. Int J Radiat Oncol Biol Phys,2001,50:705-715.
11.	BENNETT C L, Silver S M, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancerassociated anemia[J]. JAMA,2008,299(8):914-924.

1. LUDWIG H, BARRETT P, GASCON P, et al. European Cancer Anemia Survey (eECAS) defines factors surrounding anemia in thousands cancer patients[J]. Proc Am Soc Clin Oncol,2002,21:Abstract 1546.
2. LADEROUTE K, ALARCON R, BRODY, et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor[J]. Clin Cancer Res,2000,(6):2941-2950.
3. EBERT B L, BUNN H F. Regulation of the erythropoietin gene[J]. Blood,1999,94:1864-1877.
4. WEISS M J. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications[J]. Oncologist,2003, 8 Suppl 3:18-29.
5. JULIA B, SIMON L, GUIDO S, et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive Metaanalysis[J]. J Nat Cancer Inst,2005,97(7):489-498.
6. http://www.fda.gov/cder/drug/advisory/RHE2007htm[OL].
7. TSUBOI M, EZAKI K, TOBINAIi K, et al. Weekly administration of epoetin beta for chemotherapyinduced anemia in cancer patients: results of a multicenter, phase Ⅲ, randomized, doubleblind, placebocontrolled study[J]. Jpn J Clin Oncol,2009,39(3):163-168.
8. AAPRO M, SCHERHAG A, BURGER H. Effect of treatment with epoetinbeta on survival, tumour progression and thromboembolic events in patients with cancer: an updated metaanalysis of 12 randomised controlled studies including 2301 patients[J]. Br J Cancer,2008,99(1):14-22.
9. GLASPY J, CHARU V, LUO D, et al. Initiation of epoetinalpha therapy at a starting dose of 120000 units once every 3 weeks in patients with cancer receiving chemotherapy: an openlabel, multicenter study with randomized and nonrandomized treatment arms[J]. Cancer,2009,115(5):1121-1131.
10. GLASER C, MILLESI W, KORNEK G, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx[J]. Int J Radiat Oncol Biol Phys,2001,50:705-715.
11. BENNETT C L, Silver S M, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancerassociated anemia[J]. JAMA,2008,299(8):914-924.

《華西醫學》

促紅細胞生成素與腫瘤相關性貧血研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

促紅細胞生成素與腫瘤相關性貧血研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料